Table 5.
Predictors | N | n (%) | OR (95% CI) | P |
---|---|---|---|---|
Baseline VA score | ||||
<20 letters | 23 | 10 (43.5) | 1.000 | 0.028 |
20–39 letters | 56 | 25 (44.6) | 0.688 (0.227–2.091) | |
40–59 letters | 45 | 9 (20.0) | 0.277 (0.081–0.944) | |
≥60 letters | 20 | 2 (10.0) | 0.107 (0.018–0.638) | |
Duration of neovascular AMD | ||||
<1 month | 5 | 4 (80.0) | 1.000 | 0.092 |
1–6.9 months | 70 | 22 (31.4) | 0.105 (0.010–1.113) | |
7–12 months | 26 | 10 (38.5) | 0.134 (0.012–1.542) | |
>12 months | 31 | 5 (16.1) | 0.047 (0.004–0.571) | |
ARMS2 rs10490924 | ||||
GG | 16 | 6 (37.5) | 0.742 (0.190–2.897) | 0.021 |
GT | 44 | 21 (47.7) | 1.000 | |
TT | 83 | 19 (22.9) | 0.284 (0.114–0.706) |
AMD: age-related macular degeneration; CI: confidence interval; OR: odds ratio; VA: visual acuity.
Variables included in step 1 are age group, gender, baseline VA score, duration of neovascular AMD, ARMS2 rs10490924 genotype, and treatment regimen.